DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Hyatt Regency Bethesda

2015年4月13日 (月) 午前 7:00 - 2015年4月15日 (水) 午後 12:00

One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814-5326

CMC Workshop 2015

Session 8A: Modelling (Chemicals)

Session Chair(s)

Frank  Montgomery, PHD

Frank Montgomery, PHD

Global Head Regulatory CMC, GRAPSQA, AstraZeneca, United Kingdom

The Points to Consider ICH Endorsed Guide for ICH Q8/Q9/Q10 Implementation describes the use of models and their categorization from high to low impact depending on level of risk to patient when used as part of the control strategy. There are a variety of ways that this information can be incorporated into the control strategy to assure product quality and process consistency as part of a marketing application. This session will look at a variety of ways that models have been used to support marketing applications, the data and statistical analysis that was needed gain approval, and some considerations of how this could evolve in the future. For example a Design Space may be associated with RTRT, or may be part of a control strategy that includes extensive end-product testing; consequently the degree of assurance and the level of statistical confidence required can vary.

Speaker(s)

John  Lepore, PHD

John Lepore, PHD

QbD and CMC Practices Lead, Global Pharmaceutical Commercialization, Merck & Co. Inc., United States

Model Implementation: It Really Is All About the Control Strategy

Matt  Popkin, PHD

Matt Popkin, PHD

Senior Director, CMC Excellence, Global Regulatory Affairs, GSK, United Kingdom

Science and Strategy: The Role of Models in Achieving Manufacturing Flexibility

Nathan  Ide

Nathan Ide

Senior Principal Scientist, Pfizer, United States

Statistical Models and Tools for the Assessment of Process Parameter Criticality

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。